Now Approved for AFP-High* Liver Cancer (HCC) after treatment with sorafenib: CYRAMZA® (ramucirumab).
"There is an urgent need for new liver cancer treatments that take into account the things that make each patient unique, particularly for those with advanced stages of the disease," said Donna Cryer, president and CEO of the Global Liver Institute. "We welcome today’s approval and the hope it may bring to people living with this devastating disease."
CYRAMZA can help your fight
To get started, select a condition: